Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566468 | 0.99 | GSK3B (1.00) | GSK3BBACE1CDC7ROCK2MAP4K4 | |
| SCHEMBL5104864 | 0.93 | GSK3B (0.87) | GSK3BBACE1CDC7ROCK2MAP4K4 | |
| SCHEMBL27538041 | 0.83 | GSK3B (0.71) | GSK3BBACE1CDC7ROCK2MAP4K4 | |
| SCHEMBL7996126 | 0.78 | GSK3B (0.63) | GSK3BBACE1CDC7 | |
| SCHEMBL7978702 | 0.73 | GSK3B (0.59) | GSK3B | |
| SCHEMBL5098175 | 0.71 | GSK3B (0.70) | GSK3B | |
| SCHEMBL5041737 | 0.71 | GSK3B (0.64) | GSK3B | |
| SCHEMBL2403941 | 0.71 | GSK3B (0.62) | GSK3B | |
| SCHEMBL5098141 | 0.71 | GSK3B (0.69) | GSK3B | |
| SCHEMBL5104876 | 0.71 | GSK3B (0.62) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778657-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | claimed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | claimed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | claimed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885BACE1 6/4885CDC7 2083/4885 |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | GSK3A, GSK3B, CSNK2A3 | GSK3B 2/4885BACE1 68/4885CDC7 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.